Literature DB >> 9393763

Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.

H Wada1, T Enomoto, M Fujita, K Yoshino, R Nakashima, H Kurachi, T Haba, K Wakasa, K R Shroyer, M Tsujimoto, T Hongyo, T Nomura, Y Murata.   

Abstract

The pathogenesis of carcinosarcoma is still a subject of controversy. In the present study, molecular techniques were applied to determine the pathogenesis of uterine carcinosarcomas. The patterns of chromosome X inactivation were analyzed, targeting a portion of exon 1 of the human androgen receptor (HUMARA) in malignant epithelial and mesenchymal components. The presence of p53 and K-ras mutations were also analyzed. H&E-stained sections of paraffin-embedded, formalin-fixed tissues were microdissected to obtain both epithelial and nonepithelial lesions from 25 carcinosarcomas, and DNAs were extracted by proteinase K digestion. Following treatment with methylation-sensitive restriction endonuclease (HhaI or HpaII), PCR amplification was performed using nested primers targeted to the HUMARA locus. Mutations in the p53 gene and K-ras gene were found in eight (32%) and six (24%) tumors, respectively. The patterns of chromosome X inactivation were different between the carcinomatous and sarcomatous components of three carcinosarcomas, indicating that these three tumors represent collision tumors. By contrast, the patterns of chromosome X inactivation, K-ras sequence, and p53 sequence were identical in both carcinomatous and sarcomatous components in 21 carcinosarcomas, indicating that these 21 tumors represent combination tumors. One case produced equivocal results that precluded determination of whether it represented a collision or combination tumor. These observations show that although most carcinosarcomas are combination tumors, some develop as collision tumors. The determination of histogenesis in individual cases of carcinosarcoma using molecular markers may be worthwhile, because the result could help predict the prognosis of individual cases and help guide clinical management.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9393763

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Spindle cell carcinoma of head and neck: an immunohistochemical and molecular approach to its pathogenesis.

Authors:  Ruchika Gupta; Sompal Singh; Suresh Hedau; Sonu Nigam; Bhudev C Das; Ishwar Singh; Ashish Kumar Mandal
Journal:  J Clin Pathol       Date:  2006-05-26       Impact factor: 3.411

2.  Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma.

Authors:  Izumi Nishimura; Yoshihiro Ohishi; Yoshinao Oda; Junji Kishimoto; Masafumi Yasunaga; Emi Okuma; Hiroaki Kobayashi; Norio Wake; Masazumi Tsuneyoshi
Journal:  Virchows Arch       Date:  2010-11-03       Impact factor: 4.064

3.  Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.

Authors:  Laura Ardighieri; Luigi Mori; Sara Conzadori; Mattia Bugatti; Marcella Falchetti; Carla Maria Donzelli; Antonella Ravaggi; Franco E Odicino; Fabio Facchetti
Journal:  Virchows Arch       Date:  2016-04-08       Impact factor: 4.064

4.  Pancreatic carcinosarcoma: first literature report on computed tomography imaging.

Authors:  Hong-Yuan Shi; Jing Xie; Fei Miao
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

5.  Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.

Authors:  Yihua Liu; Zachary Weber; F Anthony San Lucas; Aditya Deshpande; Yasminka A Jakubek; Raed Sulaiman; Mary Fagerness; Natasha Flier; Joseph Sulaiman; Christel M Davis; Jerry Fowler; David Starks; Luis Rojas-Espaillat; Alexander J Lazar; Gareth E Davies; Erik A Ehli; Paul Scheet
Journal:  Gynecol Oncol       Date:  2018-09-05       Impact factor: 5.482

6.  Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.

Authors:  Koji Matsuo; Kohei Omatsu; Malcolm S Ross; Marian S Johnson; Mayu Yunokawa; Merieme M Klobocista; Dwight D Im; Stephen H Bush; Yutaka Ueda; Tadao Takano; Erin A Blake; Kosei Hasegawa; Tsukasa Baba; Masako Shida; Shinya Satoh; Takuhei Yokoyama; Hiroko Machida; Sosuke Adachi; Yuji Ikeda; Keita Iwasaki; Takahito M Miyake; Shiori Yanai; Masato Nishimura; Tadayoshi Nagano; Munetaka Takekuma; Satoshi Takeuchi; Tanja Pejovic; Mian Mk Shahzad; Frederick R Ueland; Joseph L Kelley; Lynda D Roman
Journal:  Gynecol Oncol       Date:  2017-02-16       Impact factor: 5.482

Review 7.  HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.

Authors:  Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

8.  URI1 amplification in uterine carcinosarcoma associates with chemo-resistance and poor prognosis.

Authors:  Yu Wang; Michael J Garabedian; Susan K Logan
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

9.  Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling.

Authors:  Maria V Guijarro; Sonika Dahiya; Laura S Danielson; Miguel F Segura; Frances M Vales-Lara; Silvia Menendez; Dorota Popiolek; Khushbakhat Mittal; Jian Jun Wei; Jiri Zavadil; Carlos Cordon-Cardo; Pier Paolo Pandolfi; Eva Hernando
Journal:  Am J Pathol       Date:  2013-06       Impact factor: 4.307

10.  Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma.

Authors:  Eric J Devor; Jillian N DE Mik; Shyam Ramachandran; Michael J Goodheart; Kimberly K Leslie
Journal:  Exp Ther Med       Date:  2012-01-25       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.